$5.54
0.00%
Nasdaq, Mon, Nov 25 2024
ISIN
US0162591038
Symbol
ALIM
Sector
Industry

Alimera Sciences, Inc. Stock price

$5.54
+0.00 0.00% 1M
+2.59 87.80% 6M
+1.22 28.24% YTD
+2.05 58.74% 1Y
-0.25 4.32% 3Y
+0.67 13.76% 5Y
-81.31 93.62% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US0162591038
Symbol
ALIM
Sector
Industry

Key metrics

Market capitalization $301.29m
Enterprise Value $362.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.64
P/S ratio (TTM) P/S ratio 3.02
P/B ratio (TTM) P/B ratio 7.48
Revenue growth (TTM) Revenue growth 69.78%
Revenue (TTM) Revenue $99.68m
EBIT (operating result TTM) EBIT $851.00k
Free Cash Flow (TTM) Free Cash Flow $-5.82m
Cash position $10.86m
EPS (TTM) EPS $-0.31
P/E forward negative
P/S forward 2.84
EV/Sales forward 3.41
Short interest 3.03%
Show more

Is Alimera Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Alimera Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Alimera Sciences, Inc. forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a Alimera Sciences, Inc. forecast:

Hold
100%

Financial data from Alimera Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
100 100
70% 70%
100%
- Direct Costs 26 26
108% 108%
26%
74 74
60% 60%
74%
- Selling and Administrative Expenses 43 43
20% 20%
43%
- Research and Development Expense 17 17
6% 6%
17%
13 13
315% 315%
13%
- Depreciation and Amortization 12 12
218% 218%
12%
EBIT (Operating Income) EBIT 0.85 0.85
108% 108%
1%
Net Profit -15 -15
39% 39%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Alimera Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alimera Sciences, Inc. Stock News

Neutral
Business Wire
3 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one n...
Neutral
GlobeNewsWire
4 months ago
ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently ...
Neutral
Business Wire
5 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alimera Sciences, Inc. (NasdaqGM: ALIM) to ANI Pharmaceuticals, Inc. (NasdaqGM: ANIP). Under the terms of the proposed transaction, shareholders of Alimera will receive $5.50 per share in cash at closing and one n...
More Alimera Sciences, Inc. News

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Head office United States
CEO Richard Eiswirth
Employees 159
Founded 2003
Website www.alimerasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today